Physician profile
Jordan Daniel Brown
NPI 1346500998
$9,747.33
in general payments reported to CMS, 2019-2025
22 companies · $723 in 2025
The $723 reported for 2025 was more than what 76% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,134 · 2020: $361 · 2021: $708 · 2022: $1,169 · 2023: $1,604 · 2024: $1,048 · 2025: $723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,374.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $3,768.85 | 2019-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $1,703.48 | 2021-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $740.54 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Janssen Pharmaceuticals, INC | $489.36 | 2019-2023 | Invega Trinza, Invega Sustenna, Spravato |
| Alkermes, INC. | $482.29 | 2019-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $479.32 | 2020-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $440.25 | 2019-2022 | |
| Neuronetics, INC. | $271.68 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $266.03 | 2019-2024 | Ingrezza |
| Axsome Therapeutics, INC. | $196.35 | 2023-2024 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $185.26 | 2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $180.20 | 2021-2025 | Trintellix |
| Allergan, INC. | $123.88 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $100.61 | 2023 | Spravato |
| Bausch Health US, LLC | $70.11 | 2020-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $63.69 | 2022-2024 | Quviviq |
| Livanova USA, INC. | $46.12 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
| Noven Therapeutics, LLC | $41.47 | 2022-2025 | Xelstrym |
| Almatica Pharma LLC | $39.62 | 2021-2023 | Gralise |
| Vanda Pharmaceuticals INC. | $34.78 | 2024 | Fanapt, Hetlioz |
| Lundbeck LLC | $11.74 | 2021 | |
| Corium, LLC | $11.70 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.